On the neuroendocrinopathy of critical illness: Perspectives for feeding and novel treatments

American Journal of Respiratory and Critical Care Medicine

Volumn 194, Issue 11, 2016, Pages 1337-1348

  Van Den Berghe, Greet ^a  

^a LABORATORY OF MOLECULAR AND CELLULAR SIGNALING   (Belgium)

Author keywords

Adrenocorticotropic hormone; Cortisol; Ghrelin; Growth hormone; Thyrotrophin releasing hormone

Indexed keywords

ADENOHYPOPHYSIS HORMONE; GROWTH HORMONE; HYPOTHALAMUS RELEASING FACTOR;

ADRENAL CORTEX ATROPHY; CRITICAL ILLNESS; HORMONE METABOLISM; HUMAN; HYPOPHYSIS ADRENAL SYSTEM; HYPOPHYSIS THYROID SYSTEM; MACRONUTRIENT; NEUROENDOCRINE DISEASE; PRIORITY JOURNAL; REVIEW; DRUG EFFECTS; FEEDING BEHAVIOR; NEUROENDOCRINOLOGY; NEUROSECRETION; PATHOLOGY; PROCEDURES;

CRITICAL ILLNESS; FEEDING BEHAVIOR; HUMANS; NEUROENDOCRINOLOGY; NEUROSECRETORY SYSTEMS; PITUITARY HORMONE-RELEASING HORMONES;

EID: 85002538352     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.201607-1516CI     Document Type: Review

References (99)

1. Van Den Berghe G, De Zegher F, Bouillon R. Clinical review 95: acute and prolonged critical illness as different neuroendocrine paradigms. J Clin Endocrinol Metab 1998;83:1827-1834.
2. Vanhorebeek I, Langouche L, Van Den Berghe G. Endocrine aspects of acute and prolonged critical illness. Nat Clin Pract Endocrinol Metab 2006;2:20-31.
3. Thorner MO, Vance ML, Laws ER, Horvath E, Kovacs K. The anterior pituitary. In: Wilson JD, Foster D, Kronenberg HM, Larsen PR, editors. Williams' textbook of endocrinology, 9th ed. Philadelphia: WB Saunders; 1998. pp. 249-340.
4. Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H, Kangawa K. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature 1999;402:656-660.
5. Cowley MA, Smith RG, Diano S, Tschöp M, Pronchuk N, Grove KL, Strasburger CJ, Bidlingmaier M, Esterman M, Heiman ML, et al. The distribution and mechanism of action of ghrelin in the CNS demonstrates a novel hypothalamic circuit regulating energy homeostasis. Neuron 2003;37:649-661.
6. Bowers CY, Momany FA, Reynolds GA, Hong A. On the in vitro and in vivo activity of a new synthetic hexapeptide that acts on the pituitary to specifically release growth hormone. Endocrinology 1984;114:1537-1545.
7. Howard AD, Feighner SD, Cully DF, Arena JP, Liberator PA, Rosenblum CI, Hamelin M, Hreniuk DL, Palyha OC, Anderson J, et al. A receptor in pituitary and hypothalamus that functions in growth hormone release. Science 1996;273:974-977.
8. Baxter RC. Changes in the IGF-IGFBP axis in critical illness. Best Pract Res Clin Endocrinol Metab 2001;15:421-434.
9. Van Den Berghe G, Baxter RC, Weekers F, Wouters P, Bowers CY, Veldhuis JD. A paradoxical gender dissociation within the growth hormone/insulin-like growth factor I axis during protracted critical illness. J Clin Endocrinol Metab 2000;85:183-192.
10. Ross R, Miell J, Freeman E, Jones J, Matthews D, PreeceM, Buchanan C. Critically ill patients have high basal growth hormone levels with attenuated oscillatory activity associated with low levels of insulin-like growth factor-I. Clin Endocrinol (Oxf) 1991;35:47-54.
11. Baxter RC, Hawker FH, To C, Stewart PM, Holman SR. Thirtyday monitoring of insulin-like growth factors and their binding proteins in intensive care unit patients. Growth Horm IGF Res 1998;8:455-463.
12. Hermansson M, Wickelgren RB, Hammarqvist F, Bjarnason R, Wennström I, Wernerman J, Carlsson B, Carlsson LM. Measurement of human growth hormone receptor messenger ribonucleic acid by a quantitative polymerase chain reaction-based assay: demonstration of reduced expression after elective surgery. J Clin Endocrinol Metab 1997;82:421-428.
13. Defalque D, Brandt N, Ketelslegers JM, Thissen JP. GH insensitivity induced by endotoxin injection is associated with decreased liver GH receptors. Am J Physiol 1999;276:E565-E572.
14. Van Den Berghe G, De Zegher F, Veldhuis JD, Wouters P, Awouters M, Verbruggen W, Schetz M, Verwaest C, Lauwers P, Bouillon R, et al. The somatotropic axis in critical illness: effect of continuous growth hormone (GH)-releasing hormone and GH-releasing peptide-2 infusion. J Clin Endocrinol Metab 1997;82:590-599.
15. Van Den Berghe G, De Zegher F, Baxter RC, Veldhuis JD, Wouters P, Schetz M, Verwaest C, Van Der Vorst E, Lauwers P, Bouillon R, et al. Neuroendocrinology of prolonged critical illness: effects of exogenous thyrotropin-releasing hormone and its combination with growth hormone secretagogues. J Clin Endocrinol Metab 1998;83:309-319.
16. Van Den Berghe G, Wouters P, Weekers F, Mohan S, Baxter RC, Veldhuis JD, Bowers CY, Bouillon R. Reactivation of pituitary hormone release and metabolic improvement by infusion of growth hormone-releasing peptide and thyrotropin-releasing hormone in patients with protracted critical illness. J Clin Endocrinol Metab 1999;84:1311-1323.
17. Yen PM. Physiological and molecular basis of thyroid hormone action. Physiol Rev 2001;81:1097-1142.
18. Bianco AC, Salvatore D, Gereben B, Berry MJ, Larsen PR. Biochemistry, cellular and molecular biology, and physiological roles of the iodothyronine selenodeiodinases. Endocr Rev 2002;23:38-89.
19. Friesema EC, Jansen J, Visser TJ. Thyroid hormone transporters. Biochem Soc Trans 2005;33:228-232.
20. Chopra IJ, Huang TS, Beredo A, Solomon DH, Chua Teco GN, Mead JF. Evidence for an inhibitor of extrathyroidal conversion of thyroxine to 3, 5, 39-triiodothyronine in sera of patients with nonthyroidal illnesses. J Clin Endocrinol Metab 1985;60:666-672.
21. Peeters RP, Wouters PJ, Kaptein E, Van Toor H, Visser TJ, Van Den Berghe G. Reduced activation and increased inactivation of thyroid hormone in tissues of critically ill patients. J Clin Endocrinol Metab 2003;88:3202-3211.
22. Michalaki M, Vagenakis AG, Makri M, Kalfarentzos F, Kyriazopoulou V. Dissociation of the early decline in serum T (3) concentration and serum IL-6 rise and TNFalpha in nonthyroidal illness syndrome induced by abdominal surgery. J Clin Endocrinol Metab 2001;86:4198-4205.
23. Van Den Berghe G. Novel insights into the neuroendocrinology of critical illness. Eur J Endocrinol 2000;143:1-13.
24. Peeters RP, Wouters PJ, Van Toor H, Kaptein E, Visser TJ, Van Den Berghe G. Serum 3, 39, 59-triiodothyronine (rT3) and 3, 5, 39-triiodothyronine/rT3 are prognostic markers in critically ill patients and are associated with postmortem tissue deiodinase activities. J Clin Endocrinol Metab 2005;90:4559-4565.
25. Van Der Poll T, Van Zee KJ, Endert E, Coyle SM, Stiles DM, Pribble JP, Catalano MA, Moldawer LL, Lowry SF. Interleukin-1 receptor blockade does not affect endotoxin-induced changes in plasma thyroid hormone and thyrotropin concentrations in man. J Clin Endocrinol Metab 1995;80:1341-1346.
26. Lim CF, Docter R, Visser TJ, Krenning EP, Bernard B, Van Toor H, De Jong M, Hennemann G. Inhibition of thyroxine transport into cultured rat hepatocytes by serum of nonuremic critically ill patients: effects of bilirubin and nonesterified fatty acids. J Clin Endocrinol Metab 1993;76:1165-1172.
27. Gardner DF, Kaplan MM, Stanley CA, Utiger RD. Effect of tri-iodothyronine replacement on the metabolic and pituitary responses to starvation. N Engl J Med 1979;300:579-584.
28. Moshang T Jr, Parks JS, Baker L, Vaidya V, Utiger RD, Bongiovanni AM, Snyder PJ. Low serum triiodothyronine in patients with anorexia nervosa. J Clin Endocrinol Metab 1975;40:470-473.
29. Casaer MP, Mesotten D, Hermans G, Wouters PJ, Schetz M, Meyfroidt G, Van Cromphaut S, Ingels C, Meersseman P, Muller J, et al. Early versus late parenteral nutrition in critically ill adults. N Engl J Med 2011;365:506-517.
30. Fivez T, Kerklaan D, Mesotten D, Verbruggen S, Wouters PJ, Vanhorebeek I, Debaveye Y, Vlasselaers D, Desmet L, Casaer MP, et al. Early versus late parenteral nutrition in critically ill children. N Engl J Med 2016;374:1111-1122.
31. Casaer MP, Wilmer A, Hermans G, Wouters PJ, Mesotten D, Van Den Berghe G. Role of disease and macronutrient dose in the randomized controlled EPaNIC trial: a post hoc analysis. Am J Respir Crit Care Med 2013;187:247-255.
32. Hermans G, Casaer MP, Clerckx B, Güiza F, Vanhullebusch T, Derde S, Meersseman P, Derese I, Mesotten D, Wouters PJ, et al. Effect of tolerating macronutrient deficit on the development of intensive-care unit acquired weakness: a subanalysis of the EPaNIC trial. Lancet Respir Med 2013;1:621-629.
33. Gunst J, Vanhorebeek I, Casaer MP, Hermans G, Wouters PJ, Dubois J, Claes K, Schetz M, Van Den Berghe G. Impact of early parenteral nutrition on metabolism and kidney injury. J Am Soc Nephrol 2013;24:995-1005.
34. Langouche L, Vander Perre S, Marques M, Boelen A, Wouters PJ, Casaer MP, Van Den Berghe G. Impact of early nutrient restriction during critical illness on the nonthyroidal illness syndrome and its relation with outcome: a randomized, controlled clinical study. J Clin Endocrinol Metab 2013;98:1006-1013.
35. Mebis L, Eerdekens A, Güiza F, Princen L, Derde S, Vanwijngaerden YM, Vanhorebeek I, Darras VM, Van Den Berghe G, Langouche L. Contribution of nutritional deficit to the pathogenesis of the nonthyroidal illness syndrome in critical illness: a rabbit model study. Endocrinology 2012;153:973-984.
36. Boelen A, Kwakkel J, Fliers E. Beyond low plasma T3: local thyroid hormone metabolism during inflammation and infection. Endocr Rev 2011;32:670-693.
37. Boelen A, Boorsma J, Kwakkel J, Wieland CW, Renckens R, Visser TJ, Fliers E, Wiersinga WM. Type 3 deiodinase is highly expressed in infiltrating neutrophilic granulocytes in response to acute bacterial infection. Thyroid 2008;18:1095-1103.
38. Van Den Berghe G, De Zegher F, Veldhuis JD, Wouters P, Gouwy S, Stockman W, Weekers F, Schetz M, Lauwers P, Bouillon R, et al. Thyrotrophin and prolactin release in prolonged critical illness: dynamics of spontaneous secretion and effects of growth hormonesecretagogues. Clin Endocrinol (Oxf) 1997;47:599-612.
39. Fliers E, Guldenaar SE, Wiersinga WM, Swaab DF. Decreased hypothalamic thyrotropin-releasing hormone gene expression in patients with nonthyroidal illness. J Clin Endocrinol Metab 1997;82:4032-4036.
40. Bacci V, Schussler GC, Kaplan TB. The relationship between serum triiodothyronine and thyrotropin during systemic illness. J Clin Endocrinol Metab 1982;54:1229-1235.
41. Damas P, Reuter A, Gysen P, Demonty J, Lamy M, Franchimont P. Tumor necrosis factor and interleukin-1 serum levels during severe sepsis in humans. Crit Care Med 1989;17:975-978.
42. Faglia G, Ferrari C, Beck-Peccoz P, Spada A, Travaglini P, Ambrosi B. Reduced plasma thyrotropin response to thyrotropin releasing hormone after dexamethasone administration in normal subjects. Horm Metab Res 1973;5:289-292.
43. Van Den Berghe G, De Zegher F, Lauwers P. Dopamine and the sick euthyroid syndrome in critical illness. Clin Endocrinol (Oxf) 1994;41:731-737.
44. Van Den Berghe G, De Zegher F, Lauwers P. Dopamine suppresses pituitary function in infants and children. Crit Care Med 1994;22:1747-1753.
45. Boelen A, Kwakkel J, Thijssen-Timmer DC, Alkemade A, Fliers E, Wiersinga WM. Simultaneous changes in central and peripheral components of the hypothalamus-pituitary-thyroid axis in lipopolysaccharide-induced acute illness in mice. J Endocrinol 2004;182:315-323.
46. Mebis L, Debaveye Y, Ellger B, Derde S, Ververs EJ, Langouche L, Darras VM, Fliers E, Visser TJ, Van Den Berghe G. Changes in the central component of the hypothalamus-pituitary-thyroid axis in a rabbit model of prolonged critical illness. Crit Care 2009;13:R147.
47. Alkemade A, Friesema EC, Kuiper GG, Wiersinga WM, Swaab DF, Visser TJ, Fliers E. Novel neuroanatomical pathways for thyroid hormone action in the human anterior pituitary. Eur J Endocrinol 2006;154:491-500.
48. Langouche L, Princen L, Gunst J, Güiza F, Derde S, Van Den Berghe G. Anterior pituitary morphology and hormone production during sustained critical illness in a rabbit model. Horm Metab Res 2013;45:277-282.
49. Mebis L, Paletta D, Debaveye Y, Ellger B, Langouche L, D'Hoore A, Darras VM, Visser TJ, Van Den Berghe G. Expression of thyroid hormone transporters during critical illness. Eur J Endocrinol 2009;161:243-250.
50. Mebis L, Langouche L, Visser TJ, Van Den Berghe G. The type II iodothyronine deiodinase is up-regulated in skeletal muscle during prolonged critical illness. J Clin Endocrinol Metab 2007;92:3330-3333.
51. Ma SF, Xie L, Pino-Yanes M, Sammani S, Wade MS, Letsiou E, Siegler J, Wang T, Infusino G, Kittles RA, et al. Type 2 deiodinase and host responses of sepsis and acute lung injury. Am J Respir Cell Mol Biol 2011;45:1203-1211.
52. Thijssen-Timmer DC, Peeters RP, Wouters P, Weekers F, Visser TJ, Fliers E, Wiersinga WM, Bakker O, Van Den Berghe G. Thyroid hormone receptor isoform expression in livers of critically ill patients. Thyroid 2007;17:105-112.
53. Van Den Berghe G, Baxter RC, Weekers F, Wouters P, Bowers CY, Iranmanesh A, Veldhuis JD, Bouillon R. The combined administration of GH-releasing peptide-2 (GHRP-2), TRH and GnRH to men with prolonged critical illness evokes superior endocrine and metabolic effects compared to treatment with GHRP-2 alone. Clin Endocrinol (Oxf) 2002;56:655-669.
54. Weekers F, Michalaki M, Coopmans W, Van Herck E, Veldhuis JD, Darras VM, Van Den Berghe G. Endocrine and metabolic effects of growth hormone (GH) compared with GH-releasing peptide, thyrotropin-releasing hormone, and insulin infusion in a rabbit model of prolonged critical illness. Endocrinology 2004;145:205-213.
55. Cooper MS, Stewart PM. Corticosteroid insufficiency in acutely ill patients. N Engl J Med 2003;348:727-734.
56. Lebrethon MC, Naville D, Begeot M, Saez JM. Regulation of corticotropin receptor number and messenger RNA in cultured human adrenocortical cells by corticotropin and angiotensin II. J Clin Invest 1994;93:1828-1833.
57. Lehoux JG, Lefebvre A, Bélisle S, Bellabarba D. Hormonal regulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase mRNA in the rat adrenal gland. J Steroid Biochem 1989;34:379-384.
58. Lehoux JG, Fleury A, Ducharme L. The acute and chronic effects of adrenocorticotropin on the levels of messenger ribonucleic acid and protein of steroidogenic enzymes in rat adrenal in vivo. Endocrinology 1998;139:3913-3922.
59. Liu J, HeikkiläP, Meng QH, Kahri AI, Tikkanen MJ, Voutilainen R. Expression of low and high density lipoprotein receptor genes in human adrenals. Eur J Endocrinol 2000;142:677-682.
60. Simpson ER, Waterman MR. Regulation by ACTH of steroid hormone biosynthesis in the adrenal cortex. Can J Biochem Cell Biol 1983;61:692-707.
61. Stocco DM, Clark BJ. Regulation of the acute production of steroids in steroidogenic cells. Endocr Rev 1996;17:221-244.
62. Vandevyver S, Dejager L, Tuckermann J, Libert C. New insights into the anti-inflammatory mechanisms of glucocorticoids: an emerging role for glucocorticoid-receptor-mediated transactivation. Endocrinology 2013;154:993-1007.
63. Miesfeld RL. Glucocorticoid action: biochemistry. In: DeGroot LJ, Jameson JL, editors. Endocrinology. Philadelphia: WB Saunders Company; 2001. pp. 1647-1654.
64. Rivier C, Vale W. Modulation of stress-induced ACTH release by corticotropin-releasing factor, catecholamines and vasopressin. Nature 1983;305:325-327.
65. Burchard K. A review of the adrenal cortex and severe inflammation: quest of the "eucorticoid" state. J Trauma 2001;51:800-814.
66. Vermes I, Beishuizen A, Hampsink RM, Haanen C. Dissociation of plasma adrenocorticotropin and cortisol levels in critically ill patients: possible role of endothelin and atrial natriuretic hormone. J Clin Endocrinol Metab 1995;80:1238-1242.
67. Marik PE, Zaloga GP. Adrenal insufficiency in the critically ill: a new look at an old problem. Chest 2002;122:1784-1796.
68. Pemberton PA, Stein PE, Pepys MB, Potter JM, Carrell RW. Hormone binding globulins undergo serpin conformational change in inflammation. Nature 1988;336:257-258.
69. Hammond GL, Smith CL, Paterson NA, Sibbald WJ. A role for corticosteroid-binding globulin in delivery of cortisol to activated neutrophils. J Clin Endocrinol Metab 1990;71:34-39.
70. Beishuizen A, Thijs LG, Vermes I. Patterns of corticosteroid-binding globulin and the free cortisol index during septic shock and multitrauma. Intensive Care Med 2001;27:1584-1591.
71. Hamrahian AH, Oseni TS, Arafah BM. Measurements of serum free cortisol in critically ill patients. N Engl J Med 2004;350:1629-1638.
72. Finlay WE, McKee JI. Serum cortisol levels in severely stressed patients. Lancet 1982;1:1414-1415.
73. Rothwell PM, Udwadia ZF, Lawler PG. Cortisol response to corticotropin and survival in septic shock. Lancet 1991;337:582-583.
74. Span LF, Hermus AR, Bartelink AK, Hoitsma AJ, Gimbrère JS, Smals AG, Kloppenborg PW. Adrenocortical function: an indicator of severity of disease and survival in chronic critically ill patients. Intensive Care Med 1992;18:93-96.
75. Annane D, Sébille V, Troché G, Raphaël JC, Gajdos P, Bellissant E. A 3-level prognostic classification in septic shock based on cortisol levels and cortisol response to corticotropin. JAMA 2000;283:1038-1045.
76. Annane D, Sébille V, Charpentier C, Bollaert PE, François B, Korach JM, Capellier G, Cohen Y, Azoulay E, Troché G, et al. Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. JAMA 2002;288:862-871.
77. Sam S, Corbridge TC, Mokhlesi B, Comellas AP, Molitch ME. Cortisol levels and mortality in severe sepsis. Clin Endocrinol (Oxf) 2004;60:29-35.
78. Bornstein SR, Chrousos GP. Clinical review 104: adrenocorticotropin (ACTH) - and non-ACTH-mediated regulation of the adrenal cortex: neural and immune inputs. J Clin Endocrinol Metab 1999;84:1729-1736.
79. Vermes I, Beishuizen A. The hypothalamic-pituitary-adrenal response to critical illness. Best Pract Res Clin Endocrinol Metab 2001;15:495-511.
80. Boonen E, Vervenne H, Meersseman P, Andrew R, Mortier L, Declercq PE, Vanwijngaerden YM, Spriet I, Wouters PJ, Vander Perre S, et al. Reduced cortisol metabolism during critical illness. N Engl JMed 2013;368:1477-1488.
81. Polito A, Sonneville R, Guidoux C, Barrett L, Viltart O, Mattot V, Siami S, Lorin De La Grandmaison G, Chrétien F, Singer M, et al. Changes in CRH and ACTH synthesis during experimental and human septic shock. Plos One 2011;6:e25905.
82. Deutschman CS, Raj NR, McGuire EO, Kelz MB. Orexinergic activity modulates altered vital signs and pituitary hormone secretion in experimental sepsis. Crit Care Med 2013;41:e368-e375.
83. Gibbison B, Angelini GD, Lightman SL. Dynamic output and control of the hypothalamic-pituitary-adrenal axis in critical illness and major surgery. Br J Anaesth 2013;111:347-360.
84. Boonen E, Meersseman P, Vervenne H, Meyfroidt G, Güiza F, Wouters PJ, Veldhuis JD, Van Den Berghe G. Reduced nocturnal ACTH-driven cortisol secretion during critical illness. Am J Physiol Endocrinol Metab 2014;306:E883-E892.
85. Boonen E, Langouche L, Janssens T, Meersseman P, Vervenne H, De Samblanx E, Pironet Z, Van Dijck L, Vander Perre S, Derese I, et al. Impact of duration of critical illness on the adrenal glands of human intensive care patients. J Clin Endocrinol Metab 2014;99:4214-4222.
86. Veldhuis JD, Keenan DM, Pincus SM. Motivations and methods for analyzing pulsatile hormone secretion. Endocr Rev 2008;29:823-864.
87. Waterhouse R. A case of suprarenal apoplexy. Lancet 1911;1:577-578.
88. Karpac J, Czyzewska K, Kern A, Brush RS, Anderson RE, Hochgeschwender U. Failure of adrenal corticosterone production in POMC-deficient mice results from lack of integrated effects of POMC peptides on multiple factors. Am J Physiol Endocrinol Metab 2008;295:E446-E455.
89. Barquist E, Kirton O. Adrenal insufficiency in the surgical intensive care unit patient. J Trauma 1997;42:27-31.
90. Boonen E, Van Den Berghe G. Endocrine responses to critical illness: novel insights and therapeutic implications. J Clin Endocrinol Metab 2014;99:1569-1582.
91. Takala J, Ruokonen E, Webster NR, Nielsen MS, Zandstra DF, Vundelinckx G, Hinds CJ. Increased mortality associated with growth hormone treatment in critically ill adults. N Engl J Med 1999;341:785-792.
92. Van Den Berghe G. Non-thyroidal illness in the ICU: a syndrome with different faces. Thyroid 2014;24:1456-1465.
93. Sprung CL, Annane D, Keh D, Moreno R, Singer M, Freivogel K, Weiss YG, Benbenishty J, Kalenka A, Forst H, et al.; CORTICUS Study Group. Hydrocortisone therapy for patients with septic shock. N Engl J Med 2008;358:111-124.
94. Mesotten D, Vanhorebeek I, Van Den Berghe G. The altered adrenal axis and treatment with glucocorticoids during critical illness. Nat Clin Pract Endocrinol Metab 2008;4:496-505.
95. Van Den Berghe G, Wouters P, Weekers F, Verwaest C, Bruyninckx F, Schetz M, Vlasselaers D, Ferdinande P, Lauwers P, Bouillon R. Intensive insulin therapy in critically ill patients. N Engl J Med 2001;345:1359-1367.
96. Van Den Berghe G, Wilmer A, Hermans G, Meersseman W, Wouters PJ, Milants I, Van Wijngaerden E, Bobbaers H, Bouillon R. Intensive insulin therapy in the medical ICU. N Engl J Med 2006;354:449-461.
97. Vlasselaers D, Milants I, Desmet L, Wouters PJ, Vanhorebeek I, Van Den Heuvel I, Mesotten D, Casaer MP, Meyfroidt G, Ingels C, et al. Intensive insulin therapy for patients in paediatric intensive care: a prospective, randomised controlled study. Lancet 2009;373:547-556.
98. Gielen M, Mesotten D, Wouters PJ, Desmet L, Vlasselaers D, Vanhorebeek I, Langouche L, Van Den Berghe G. Effect of tight glucose control with insulin on the thyroid axis of critically ill children and its relation with outcome. J Clin Endocrinol Metab 2012;97:3569-3576.
99. Finfer S, Chittock DR, Su SY, Blair D, Foster D, Dhingra V, Bellomo R, Cook D, Dodek P, Henderson WR, et al.; NICE-SUGAR Study Investigators. Intensive versus conventional glucose control in critically ill patients. N Engl J Med 2009;360:1283-1297.